Tag: Tricuspid

CorMatrix® Cardiovascular, Inc. receives FDA approval to expand and enroll 20 additional patients in the adult arm of its early feasibility IDE study of the Cor® TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Feb. 7, 2020 /PRNewswire/ — CorMatrix®Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for […]

TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation

Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a €22 Million ($25.4 Million) Series B financing […]

NaviGate Cardiac Structures Inc. (“NCSI”) reports GATE™ bioprosthesis as the first transcatheter valve replacement in Canada to treat tricuspid regurgitation

LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that on 2 Feb. 2018, its catheter-guided GATE™ valved-stent bioprosthesis beame the first Canadian orthotopic valve replacement to treat severe tricuspid regurgitation. The procedure was performed at the Quebec Heart and […]

Mitralign Release: SCOUT I Study Using Trialign System for Transcatheter Tricuspid Repair Continues to Show Positive Outcomes at 1 Year

DENVER–(BUSINESS WIRE)– Mitralign, Inc.., an innovative developer of transcatheter tricuspid and mitral valve repair solutions, today released 1 year follow up data from the SCOUT I Early Feasibility Study designed to evaluate the performance of its Trialign™ System. The data presented […]

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation

LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed […]